WallStreetZenWallStreetZen

NASDAQ: KROS
Keros Therapeutics Inc Stock Ownership - Who owns Keros Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Keros Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jean Jacques BienaimeDirector2026-04-151,000$11.70
$11.70kBuy
Jasbir SeehraCHIEF EXECUTIVE OFFICER2026-04-0255,000$0.30
$16.50kBuy
Jean Jacques BienaimeDirector2026-03-092,000$11.21
$22.42kBuy
Jasbir SeehraCHIEF EXECUTIVE OFFICER2026-02-197,015$16.17
$113.43kSell
Keith RegnanteCHIEF FINANCIAL OFFICER2026-02-184,739$16.35
$77.48kSell
Lorena Raquel LernerChief Science Officer2026-02-183,873$16.35
$63.32kSell
Esther ChoSVP General Counsel2026-02-184,745$16.35
$77.58kSell
Julius KnowlesDirector2025-11-21191,527$17.75
$3.40MSell
Carl L. GordonDirector2025-11-21140,057$17.75
$2.49MSell
Carl L. GordonDirector2025-11-2174,465$17.75
$1.32MSell

1 of 3

KROS insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KROS insiders and whales buy or sell their stock.

KROS Shareholders

What type of owners hold Keros Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Blackrock Inc11.62%2,290,532$27.51MInstitution
Alon Lazarus10.33%2,036,140$24.45MInsider
Arkin Bio Ventures Limited Partnership10.21%2,013,102$24.18MInsider
Vanguard Group Inc7.74%1,525,355$18.32MInstitution
Arrowstreet Capital Limited Partnership6.77%1,334,516$16.03MInstitution
Pontifax Management 4 GP 2015 Ltd6.27%1,236,912$14.86MInsider
Carl L. Gordon5.93%1,170,119$14.05MInsider
Orbimed Advisors LLC5.91%1,164,869$13.99MInsider
State Street Corp5.46%1,075,993$12.92MInstitution
Madison Avenue Partners LP4.18%823,707$9.89MInstitution

1 of 3

KROS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KROS68.83%31.17%Net SellingNet Buying
CDXS46.64%53.36%Net SellingNet Selling
CNTX70.98%1.43%Net Buying
CAMP59.53%40.47%Net Buying
ARCT83.37%12.98%Net Buying
View Top Biotech Stocks

Keros Therapeutics Stock Ownership FAQ

Who owns Keros Therapeutics?

Keros Therapeutics (NASDAQ: KROS) is owned by 101.81% institutional shareholders, 46.12% Keros Therapeutics insiders, and 0.00% retail investors. Alon Lazarus is the largest individual Keros Therapeutics shareholder, owning 2.04M shares representing 10.33% of the company. Alon Lazarus's Keros Therapeutics shares are currently valued at $23.72M.

If you're new to stock investing, here's how to buy Keros Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.